QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place November 11, 2026, in New York City.

Chief Financial Officer Jay Jennings will deliver a company presentation and participate in one-on-one meetings with investors. The presentation will be available via live webcast and as a replay using the link below. Details are as follows:

Investors interested in scheduling a meeting with Mr. Jennings should contact their Canaccord Genuity representative or QT Imaging’s investor relations team at ir@qtimaging.com.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems that use low-frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105715736/en/